Pharmacokinetic analysis of (6S)-5-formyltetrahydrofolate (1-CF), (6R)-5-formyltetrahydrofolate (d-CF) and 5-methyltetrahydrofolate (5-CH3-THF) in patients receiving constant i.v. infusion of high-dose (6R,S)-5-formyltetrahydrofolate (leucovorin).
Pharmacokinetic analysis of (6S)-5-formyltetrahydrofolate (1-CF), (6R)-5-formyltetrahydrofolate (d-CF) and 5-methyltetrahydrofolate (5-CH3-THF) in patients receiving constant i.v. infusion of high-dose (6R,S)-5-formyltetrahydrofolate (leucovorin).
复制标题
(6S)-5-甲酰四氢叶酸 (1-CF)、(6R)-5-甲酰四氢叶酸 (d-CF) 和 5-甲基四氢叶酸 (5-CH3-THF) 在接受恒定静脉注射的患者中的药代动力学分析
DOI：
10.1007/978-1-4684-5607-3_5
复制
发表时间：
1988
影响因子：
--
通讯作者：
Newman,EM
中科院分区：
文献类型：
--
作者：
Straw,JA;Newman,EM
亚叶酸钙和氟尿嘧啶联合应用的生化基础假设，大剂量亚叶酸钙的应用将增加活性叶酸的内源库，并增强胸苷合成酶-FdUMP-亚甲基四氢叶酸复合体的形成和/或稳定性(1)。如果要选择能产生足够的血浆活性叶酸水平的亚叶酸，了解亚叶酸钙及其活性代谢物的药代动力学行为是至关重要的。
The biochemical rationale for the combination of leucovorin and fluorouracil presumes that administration of large doses of leucovorin will increase the endogenous pools of active folates and enhance the formation and/or stability of the thymidylate synthase-FdUMP-methylenetetrahydrofolate complex (1). A knowledge of the pharmacokinetic behavior of leucovorin and its active metabolite is essential if one is to select doses of leucovorin which will produce adequate plasma levels of active folates.